29 citations
,
July 2012 in “The Journal of Sexual Medicine” In this study using a rat model, discontinuing dutasteride improved some relaxant responses but did not fully restore erectile function, indicating a potential time-dependent detriment of the drug.
218 citations
,
December 2011 in “Advances in Urology” This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.
25 citations
,
August 2011 in “The Journal of Allergy and Clinical Immunology” Finasteride caused a rare skin rash in a man, which improved after stopping the medication.
10 citations
,
June 2011 in “Archives of Dermatology” Finasteride caused blisters on hands and feet.
29 citations
,
May 2011 in “Journal of Cataract and Refractive Surgery” This case report suggests a possible association between long-term finasteride use for male pattern baldness and the development of cataracts and intraoperative floppy-iris syndrome in a patient.
185 citations
,
March 2011 in “The Journal of Sexual Medicine” This study found that 94% of healthy men reported low libido and 92% reported erectile dysfunction as persistent sexual side effects after using finasteride for male pattern hair loss, with these effects lasting on average 40 months post-discontinuation.
223 citations
,
December 2010 in “The Journal of Sexual Medicine” This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.
260 citations
,
July 2010 in “Cell” This study identifies mutations in the SRD5A3 gene as a cause of a new type of congenital disorder of glycosylation, impacting mental, ophthalmologic, and cerebellar functions.
32 citations
,
May 2010 in “Pharmacopsychiatry” This article investigates whether finasteride influences adult hippocampal neurogenesis related to depression and reports no new clinical findings; the authors suggest further research on its neurosteroid inhibition.
19 citations
,
September 2006 in “Journal of Neurophysiology” In this study, researchers found that after reducing GABAergic inhibition in rats' auditory midbrain, the brain quickly compensates by increasing local neurosteroid synthesis to maintain balance in neural circuits.
82 citations
,
August 2006 in “Pharmacology, Biochemistry and Behavior” This review proposes focusing on relationships between neuroactive steroids and psychiatric disorder symptoms, rather than relying on traditional disorder classifications, and reports no new clinical findings.
269 citations
,
May 2002 in “Journal of Neuroscience” This study observed that acute stress in rats increased neurosteroid levels linked to enhanced GABA(A) receptor function, raising seizure thresholds, while similar effects were seen in mice with deoxycorticosterone administration.
237 citations
,
December 2001 in “Urology” This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.
25 citations
,
September 1998 in “The Journal of Steroid Biochemistry and Molecular Biology” This study concludes that rhesus macaques are a suitable model for testing the pharmacological properties of finasteride and other 5aR inhibitors, due to their biochemical similarity to humans.
1054 citations
,
February 1998 in “The New England Journal of Medicine” In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.
98 citations
,
April 1997 in “The Journal of Steroid Biochemistry and Molecular Biology” Finasteride effectively blocks rat enzymes, but with varying methods and strength.
67 citations
,
February 1997 in “Teratology” This study demonstrated that high oral doses of finasteride caused external genital abnormalities in male rhesus monkey fetuses, but intravenous doses did not lead to abnormalities.
136 citations
,
March 1996 in “Journal of the American Chemical Society” This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.
26 citations
,
July 1995 in “Neurobiology of Aging” Finasteride affects prostate weights and pituitary activity differently with age.
70 citations
,
June 1993 in “Biochemistry” This study found that the binding of finasteride to the enzyme 5a-reductase occurs at a slower rate than previously assumed, complicating the estimation of its real inhibitory constant.
